A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Brief description of study

This research is about testing a new medicine called ASP2138 for people with metastatic or locally advanced unresectable gastric or GEJ adenocarcinoma or metastatic pancreatic adenocarcinoma expressing CLDN18.2. The study team will check if the medicine has few side effects and figure out the right amount to give patients. First, they'll test different doses to see which one works best and doesn't cause too many side effects. Then, they'll give this dose to more people to see if it helps their tumors. The study has different time periods, like when they check if someone's eligible for the study, when they get the treatment, and when they follow up after treatment. They're careful about how much medicine they give and will watch closely for any bad reactions. The goal is to find a safe and helpful dose for these cancers.

Clinical Study Identifier: s23-00232
ClinicalTrials.gov Identifier: NCT05365581
Principal Investigator: Jennifer Chuy.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.